Alzamend Neuro, Inc. (ALZN)

Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $8.70 million. The enterprise value is $2.81 million.

Market Cap	8.70M
Enterprise Value	2.81M

Important Dates

The last earnings date was Wednesday, September 10, 2025, after market close.

Earnings Date	Sep 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Alzamend Neuro has 3.44 million shares outstanding. The number of shares has increased by 1,121.34% in one year.

Current Share Class	3.44M
Shares Outstanding	3.44M
Shares Change (YoY)	+1,121.34%
Shares Change (QoQ)	+196.09%
Owned by Insiders (%)	0.18%
Owned by Institutions (%)	0.46%
Float	3.42M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.46
P/TBV Ratio	1.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.03

Current Ratio	6.03
Quick Ratio	5.72
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-732.97

Financial Efficiency

Return on equity (ROE) is -302.25% and return on invested capital (ROIC) is -188.65%.

Return on Equity (ROE)	-302.25%
Return on Assets (ROA)	-97.46%
Return on Invested Capital (ROIC)	-188.65%
Return on Capital Employed (ROCE)	-116.68%
Revenue Per Employee	n/a
Profits Per Employee	-$976,194
Employee Count	7
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.86% in the last 52 weeks. The beta is -0.28, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (5Y)	-0.28
52-Week Price Change	-81.86%
50-Day Moving Average	2.40
200-Day Moving Average	5.62
Relative Strength Index (RSI)	55.65
Average Volume (20 Days)	173,579

Short Selling Information

The latest short interest is 137,415, so 3.99% of the outstanding shares have been sold short.

Short Interest	137,415
Short Previous Month	137,126
Short % of Shares Out	3.99%
Short % of Float	4.01%
Short Ratio (days to cover)	2.13

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-6.23M
Pretax Income	-6.24M
Net Income	-6.83M
EBITDA	-6.17M
EBIT	-6.23M
Earnings Per Share (EPS)	-$7.15

Balance Sheet

The company has $5.62 million in cash and n/a in debt, giving a net cash position of $5.62 million or $1.63 per share.

Cash & Cash Equivalents	5.62M
Total Debt	n/a
Net Cash	5.62M
Net Cash Per Share	$1.63
Equity (Book Value)	5.34M
Book Value Per Share	1.70
Working Capital	4.95M

Cash Flow

In the last 12 months, operating cash flow was -$7.88 million and capital expenditures -$210,000, giving a free cash flow of -$8.09 million.

Operating Cash Flow	-7.88M
Capital Expenditures	-210,000
Free Cash Flow	-8.09M
FCF Per Share	-$2.35

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,121.34%
Shareholder Yield	-1,121.34%
Earnings Yield	-81.09%
FCF Yield	-95.94%

Analyst Forecast

The average price target for Alzamend Neuro is $42.00, which is 1,560.08% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$42.00
Price Target Difference	1,560.08%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 12, 2025. It was a reverse split with a ratio of 1:9.

Last Split Date	May 12, 2025
Split Type	Reverse
Split Ratio	1:9

Scores

Altman Z-Score	n/a
Piotroski F-Score	1